Analyst Price Targets — RHHBY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:17 am | — | HSBC | $57.00 | $48.66 | TheFly | Roche price target raised to $57 from $50 at HSBC |
| October 2, 2025 9:07 am | Rajesh Kumar | HSBC | $50.00 | $44.83 | TheFly | Roche upgraded to Buy from Hold at HSBC (yesterday) |
| June 27, 2022 8:11 am | — | Cowen & Co. | $48.00 | $41.64 | Benzinga | Cowen & Co. Maintains Outperform on Roche Holding, Lowers Price Target to $48 |
Latest News for RHHBY
WORCESTER, Mass., July 15, 2026 /PRNewswire/ -- The Hanover Insurance Group, Inc., (NYSE: THG), a leading property and casualty insurance company, announced today that John "Jack" C.
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RHHBY.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.